Lundbeck increases its share capital by 9,772 shares (0.005% of outstanding shares) as a result of employee warrant exercise
Lundbeck increases its share capital by 9,772 shares (0.005% of outstanding shares) as a result of employee warrant exercise.
Valby, Denmark, 16 May 2013 - H. Lundbeck A/S (Lundbeck) today announced an increase of its share capital by DKK 48,860 as a consequence of the exercise of employee warrants.
The new shares are issued without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 8,803 shares at DKK 97, and 969 shares at DKK 102. Proceeds to the company are DKK 952,729 (approximately USD 165,980). The increase corresponds to approximately 0.005% of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2013. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Commerce and Companies Agency. Lundbeck's current share capital amounts to DKK 980,682,555 and will after the capital increase be DKK 980,731,415. The capital increase is expected to be finalized shortly.
Lundbeck contact
| Investors: | Media: |
| Palle Holm Olesen | Mads Kronborg |
| Chief Specialist, Head of Investor Relations | Media Relations Manager |
| PALO@lundbeck.com | MAVK@lundbeck.com |
| +45 36 43 24 26 | +45 36 43 28 51 |
| Jens Høyer | |
| Investor Relations Officer | |
| JSHR@lundbeck.com | |
| +45 36 43 33 86 | |
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today, Lundbeck employs approximately 5.800 people worldwide, 2.000 of whom are based in Denmark. We have employees in 57 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France, Italy and Mexico and research centers in Denmark, China and the United States. Lundbeck generated revenue of approximately DKK 14.8 billion in 2012. For more information, please visit www.lundbeck.com.